Background/Aim: To determine the mutations in the CYP21A2 gene in Greek-Cypriots with congenital adrenal hyperplasia (CAH) and attempt a genotype-phenotype correlation. Subjects and Methods: Molecular analysis was performed by multiplex ligation-dependent probe amplification and direct sequencing of PCR products of the CYP21A2 gene in 32 CAH patients. Results: The most frequent genetic defect in the classic salt-wasting and simple virilizing forms was the IVS2-13A/C>G (55%) mutation, followed by Large lesion (20%) and in the non-classical form, the p.V281L (79.5%). Genotypes were categorized in 4 mutation groups (null, A, B and C). All 3 patients in the null group manifested the salt-wasting form and all 6 patients in mutation group A presented with the classical form. One patient in group B had the simple virilizing form and 22 patients in group C exhibited the non-classical form. Conclusion: The spectrum of mutations of the CYP21A2 gene in our population is comparable to the most common reported in similar ethnic groups. The knowledge of the ethnic specificity of the CYP21A2 mutations represents a valuable diagnostic tool for all forms of CAH.

Keywords:
Congenital adrenal hyperplasia, CYP21A2 gene, Mutations
1.
Merke DP, Bornstein SR: Congenital adrenal hyperplasia. Lancet 2005;365:2125–2136.
2.
Speiser PW, White PC: Congenital adrenal hyperplasia. N Engl J Med 2003;349:776–788.
3.
Forest MG: Recent advances in the diagnosis and management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Hum Reprod Update 2004;10:469–485.
4.
Morel Y, Miller WL: Clinical and molecular genetics of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Adv Hum Genet 1991;20:1–68.
5.
Carroll MC, Campbell RD, Porter RR: Mapping of steroid 21-hydroxylase genes adjacent to complement component C4 genes in HLA, the major histocompatibility complex in man. Proc Natl Acad Sci USA 1985;82:521–525.
6.
Urabe K, Kimura A, Harada F, Iwanaga T, Sasazuki T: Gene conversion in steroid 21-hydroxylase genes. Am J Hum Genet 1990;46:1178–1186.
7.
Van der Kamp HJ, Wit JM: Neonatal screening for congenital adrenal hyperplasia. Eur J Endocrinol 2004;151(suppl 3):U71–U75.
8.
Pang S: Congenital adrenal hyperplasia. Endocrinol Metab Clin North Am 1997;26:853–891.
9.
Higashi Y, Yoshioka H, Yamane M, Gotoh O, Fujii-Kuriyama Y: Complete nucleotide sequence of two steroid 21-hydroxylase genes tandemly arranged in human chromosome: a pseudogene and a genuine gene. Proc Natl Acad Sci USA 1986;83:2841–2845.
10.
White PC, New MI, Dupont B: Structure of human steroid 21-hydroxylase genes. Proc Natl Acad Sci USA 1986;83:5111–5115.
11.
Donohoue PA, Jospe N, Migeon CJ, Van Dop C: Two distinct areas of unequal crossingover within the steroid 21-hydroxylase genes produce absence of CYP21B. Genomics 1989;5:397–406.
12.
Tusie-Luna MT, Traktman P, White PC: Determination of functional effects of mutations in the steroid 21-hydroxylase gene (CYP21) using recombinant vaccinia virus. J Biol Chem 1990;265:20916–20922.
13.
Wilson RC, Mercado AB, Cheng KC, New MI: Steroid 21-hydroxylase deficiency: genotype may not predict phenotype. J Clin Endocrinol Metab 1995;80:2322–2329.
14.
Wedell A: Molecular genetics of congenital adrenal hyperplasia (21-hydroxylase deficiency): implications for diagnosis, prognosis and treatment. Acta Paediatr 1998;87:159–164.
15.
Mercado AB, Wilson RC, Cheng KC, Wei JQ, New MI: Prenatal treatment and diagnosis of congenital adrenal hyperplasia owing to steroid 21-hydroxylase deficiency. J Clin Endocrinol Metab 1995;80:2014–2020.
16.
Krone N, Roscher AA, Schwarz HP, Braun A: Comprehensive analytical strategy for mutation screening in 21-hydroxylase deficiency. Clin Chem 1998;44:2075–2082.
17.
Wilson RC, Nimkarn S, Dumic M, Obeid J, Azar MR, Najmabadi H, Saffari F, New MI: Ethnic-specific distribution of mutations in 716 patients with congenital adrenal hyperplasia owing to 21-hydroxylase deficiency. Mol Genet Metab 2007;90:414–421.
18.
Dracopoulou-Vabouli M, Maniati-Christidi M, Dacou-Voutetakis C: The spectrum of molecular defects of the CYP21 gene in the Hellenic population: variable concordance between genotype and phenotype in the different forms of congenital adrenal hyperplasia. J Clin Endocrinol Metab 2001;86:2845–2848.
19.
Wasniewska M, Di Pasquale G, Rulli I, Salzano G, Caruso M, Indovina S, Di Pasquale L, Zirilli G, De Luca F: In Sicilian ethnic group non-classical congenital adrenal hyperplasia is frequently associated with a very mild genotype. J Endocrinol Invest 2007;30:181–185.
20.
Wasniewska M, Caruso M, Indovina S, Crisafulli G, Mirabelli S, Salzano G, Arrigo T, De Luca F: Salt-wasting congenital adrenal hyperplasia: genotypical peculiarities in a Sicilian ethnic group. J Endocrinol Invest 2008;31:607–609.
21.
Abid F, Tardy V, Gaouzi A, El Hessni A, Morel Y, Chabraoui L: CYP21A2 gene mutation analysis in Moroccan patients with classic form of 21-hydroxylase deficiency: high regional prevalence of p.Q318X mutation and identification of a novel p.L353R mutation. Clin Chem Lab Med 2008;46:1707–1713.
22.
Sadeghi F, Yurur-Kutlay N, Berberoglu M, Cetinkaya E, Aycan Z, Kara C, Ilgin Ruhi H, Ocal G, Siklar Z, Elhan A, Tukun A: Identification of frequency and distribution of the nine most frequent mutations among patients with 21-hydroxylase deficiency in Turkey. J Pediatr Endocrinol Metab 2008;21:781–787.
23.
Kharrat M, Tardy V, M’Rad R, Maazoul F, Jemaa LB, Refai M, Morel Y, Chaabouni H: Molecular genetic analysis of Tunisian patients with a classic form of 21-hydroxylase deficiency: identification of four novel mutations and high prevalence of Q318X mutation. J Clin Endocrinol Metab 2004;89:368–374.
24.
Wedell A, Luthman H: Steroid 21-hydroxylase deficiency: two additional mutations in salt-wasting disease and rapid screening of disease-causing mutations. Hum Mol Genet 1993;2:499–504.
25.
Wedell A, Thilen A, Ritzen EM, Stengler B, Luthman H: Mutational spectrum of the steroid 21-hydroxylase gene in Sweden: implications for genetic diagnosis and association with disease manifestation. J Clin Endocrinol Metab 1994;78:1145–1152.
26.
Speiser PW, Dupont J, Zhu D, Serrat J, Buegeleisen M, Tusie-Luna MT, Lesser M, New MI, White PC: Disease expression and molecular genotype in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Invest 1992;90:584–595.
27.
White PC, Vitek A, Dupont B, New MI: Characterization of frequent deletions causing steroid 21-hydroxylase deficiency. Proc Natl Acad Sci USA 1988;85:4436–4440.
28.
Wedell A, Stengler B, Luthman H: Characterization of mutations on the rare duplicated C4/CYP21 haplotype in steroid 21-hydroxylase deficiency. Hum Genet 1994;94:50–54.
29.
Globerman H, Amor M, Parker KL, New MI, White PC: Nonsense mutation causing steroid 21-hydroxylase deficiency. J Clin Invest 1988;82:139–144.
30.
Rodrigues NR, Dunham I, Yu CY, Carroll MC, Porter RR, Campbell RD: Molecular characterization of the HLA-linked steroid 21-hydroxylase B gene from an individual with congenital adrenal hyperplasia. EMBO J 1987;6:1653–1661.
31.
Higashi Y, Hiromasa T, Tanae A, Miki T, Nakura J, Kondo T, Ohura T, Ogawa E, Nakayama K, Fujii-Kuriyama Y: Effects of individual mutations in the P-450(C21) pseudogene on the P-450(C21) activity and their distribution in the patient genomes of congenital steroid 21-hydroxylase deficiency. J Biochem 1991;109:638–644.
32.
Amor M, Parker KL, Globerman H, New MI, White PC: Mutation in the CYP21B gene (Ile-172-Asn) causes steroid 21-hydroxylase deficiency. Proc Natl Acad Sci USA 1988;85:1600–1604.
33.
Nikoshkov A, Lajic S, Holst M, Wedell A, Luthman H: Synergistic effect of partially inactivating mutations in steroid 21-hydroxylase deficiency. J Clin Endocrinol Metab 1997;82:194–199.
34.
Barbaro M, Lajic S, Baldazzi L, Balsamo A, Pirazzoli P, Cicognani A, Wedell A, Cacciari E: Functional analysis of two recurrent amino acid substitutions in the CYP21 gene from Italian patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2004;89:2402–2407.
35.
Krone N, Braun A, Roscher AA, Knorr D, Schwarz HP: Predicting phenotype in steroid 21-hydroxylase deficiency? Comprehensive genotyping in 155 unrelated, well-defined patients from southern Germany. J Clin Endocrinol Metab 2000;85:1059–1065.
36.
Dolzan V, Solyom J, Fekete G, Kovacs J, Rakosnikova V, Votava F, Lebl J, Pribilincova Z, Baumgartner-Parzer SM, Riedl S, Waldhauser F, Frisch H, Stopar-Obreza M, Krzisnik C, Battelino T: Mutational spectrum of steroid 21-hydroxylase and the genotype-phenotype association in Middle European patients with congenital adrenal hyperplasia. Eur J Endocrinol 2005;153:99–106.
37.
Wilson RC, Wei JQ, Cheng KC, Mercado AB, New MI: Rapid deoxyribonucleic acid analysis by allele-specific polymerase chain reaction for detection of mutations in the steroid 21-hydroxylase gene. J Clin Endocrinol Metab 1995;80:1635–1640.
38.
Owerbach D, Ballard AL, Draznin MB: Salt-wasting congenital adrenal hyperplasia: detection and characterization of mutations in the steroid 21-hydroxylase gene, CYP21, using the polymerase chain reaction. J Clin Endocrinol Metab 1992;74:553–558.
39.
Ezquieta B, Oliver A, Gracia R, Gancedo PG: Analysis of steroid 21-hydroxylase gene mutations in the Spanish population. Hum Genet 1995;96:198–204.
40.
Carrera P, Bordone L, Azzani T, Brunelli V, Garancini MP, Chiumello G, Ferrari M: Point mutations in Italian patients with classic, non-classic, and cryptic forms of steroid 21-hydroxylase deficiency. Hum Genet 1996;98:662–665.
41.
Jaaskelainen J, Levo A, Voutilainen R, Partanen J: Population-wide evaluation of disease manifestation in relation to molecular genotype in steroid 21-hydroxylase (CYP21) deficiency: good correlation in a well defined population. J Clin Endocrinol Metab 1997;82:3293–3297.
42.
Dardis A, Bergada I, Bergada C, Rivarola M, Belgorosky A: Mutations of the steroid 21-hydroxylase gene in an Argentinean population of 36 patients with classical congenital adrenal hyperplasia. J Pediatr Endocrinol Metab 1997;10:55–61.
43.
Fardella CE, Poggi H, Pineda P, Soto J, Torrealba I, Cattani A, Oestreicher E, Foradori A: Salt-wasting congenital adrenal hyperplasia: detection of mutations in CYP21B gene in a Chilean population. J Clin Endocrinol Metab 1998;83:3357–3360.
44.
Bachega TA, Billerbeck AE, Madureira G, Marcondes JA, Longui CA, Leite MV, Arnhold IJ, Mendonca BB: Molecular genotyping in Brazilian patients with the classical and nonclassical forms of 21-hydroxylase deficiency. J Clin Endocrinol Metab 1998;83:4416–4419.
45.
Lako M, Ramsden S, Campbell RD, Strachan T: Mutation screening in British 21-hydroxylase deficiency families and development of novel microsatellite-based approaches to prenatal diagnosis. J Med Genet 1999;36:119–124.
46.
Kotaska K, Lisa L, Prusa R: Common CYP21 gene mutations in Czech patients and statistical analysis of worldwide mutation distribution. Cent Eur J Public Health 2003;11:124–128.
47.
Rumsby G, Avey CJ, Conway GS, Honour JW: Genotype-phenotype analysis in late onset 21-hydroxylase deficiency in comparison to the classical forms. Clin Endocrinol (Oxf) 1998;48:707–711.
48.
Bobba A, Marra E, Giannattasio S, Iolascon A, Monno F, Di Maio S: 21-Hydroxylase deficiency in Italy: a distinct distribution pattern of CYP21 mutations in a sample from southern Italy. J Med Genet 1999;36:648–650.
49.
Levo A, Jaaskelainen J, Sistonen P, Siren MK, Voutilainen R, Partanen J: Tracing past population migrations: genealogy of steroid 21-hydroxylase (CYP21) gene mutations in Finland. Eur J Hum Genet 1999;7:188–196.
50.
Balsamo A, Cacciari E, Baldazzi L, Tartaglia L, Cassio A, Mantovani V, Piazzi S, Cicognani A, Pirazzoli P, Mainetti B, Zappulla F: CYP21 analysis and phenotype/genotype relationship in the screened population of the Italian Emilia-Romagna region. Clin Endocrinol (Oxf) 2000;53:117–125.
51.
Baumgartner-Parzer SM, Nowotny P, Heinze G, Waldhausl W, Vierhapper H: Carrier frequency of congenital adrenal hyperplasia (21-hydroxylase deficiency) in a middle European population. J Clin Endocrinol Metab 2005;90:775–778.
52.
Robins T, Carlsson J, Sunnerhagen M, Wedell A, Persson B: Molecular model of human CYP21 based on mammalian CYP2C5: structural features correlate with clinical severity of mutations causing congenital adrenal hyperplasia. Mol Endocrinol 2006;20:2946–2964.
53.
Tusie-Luna MT, Speiser PW, Dumic M, New MI, White PC: A mutation (Pro-30 to Leu) in CYP21 represents a potential nonclassic steroid 21-hydroxylase deficiency allele. Mol Endocrinol 1991;5:685–692.
54.
White PC, New MI: Genetic basis of endocrine disease 2: congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 1992;74:6–11.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.